Trials / Completed
CompletedNCT00652483
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 433 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brimonidine ophthalmic solution 0.1% | 1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00) |
| DRUG | Brimonidine ophthalmic solution 0.2% | 1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00) |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2003-12-01
- Completion
- 2004-09-01
- First posted
- 2008-04-03
- Last updated
- 2008-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00652483. Inclusion in this directory is not an endorsement.